J. Misset

发表

Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.

A. Roquancourt, R. Rouzier, F. Penault-Llorca, 2012 .

The Yield of 18F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study

D. Groheux, M. Espié, E. Hindié, 2011, The Journal of Nuclear Medicine.

Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.

J Lellouch, J. Lellouch, F. Lévi, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18F]-FDG positron imaging in clinical management of lymphoma patients.

J. Talbot, C. Haioun, M. Meignan, 2001, Critical reviews in oncology/hematology.

Chemotherapy for metastatic breast cancer-report of a European expert panel.

M. Piccart, J. Crown, G. von Minckwitz, 2002, The Lancet. Oncology.

Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function

J. Misset, D. Cupissol, G. Bastian, 2000, Cancer Chemotherapy and Pharmacology.

¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.

D. Groheux, P. Merlet, M. Espié, 2014, European journal of radiology.

J. Cassidy, J. Misset, 2002, Seminars in oncology.

Exacerbation of oxaliplatin neurosensory toxicity following surgery.

F. Goldwasser, J. Misset, E. Savier, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A bulky single mass of the liver that revealed a primary hepatic leiomyosarcoma

V. Paradis, E. Raymond, J. Belghiti, 2006, Oncologie.

Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.

J. Misset, 2002, Seminars in oncology.

Combination of Topotecan and Oxaliplatin in Inoperable Hepatocellular Cancer Patients

F. Goldwasser, J. Misset, D. Azoulay, 2002, American journal of clinical oncology.

Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.

F. Lévi, F. Goldwasser, J. Misset, 2000, Anti-cancer drugs.

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.

F. Lévi, G. Milano, B. Hecquet, 1990, Journal of the National Cancer Institute.

[Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].

M. Meignan, J. Misset, S. Askienazy, 2002, Bulletin du cancer.

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.

G. Vassal, P. Hérait, J. Misset, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.

F. Goldwasser, J. Misset, C. Jasmin, 1999, Anti-cancer drugs.

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

P. Fumoleau, C. Hill, P. Fargeot, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

H. Rosing, E. Brain, J. Misset, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxoids in combination chemotherapy for metastatic breast cancer

P. Fumoleau, V. Diéras, J. Misset, 1996, Anti-cancer drugs.

Pharmacokinetics and safety profile of oxaliplatin.

M. Marty, J. Misset, J. Extra, 1998, Seminars in oncology.

Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.

J. Misset, E. Cortesi, E. Gamelin, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

A. Reinberg, F. Lévi, H. Bismuth, 1992, Cancer.

The rhythmic organization of the immune network : implications for the chronopharmacologic delivery of interferons, interleukins and cyclosporin

F. Lévi, R. Adam, H. Bismuth, 1992 .

2007 Standards, Options, and Recommendations: Use of erythropoiesis‐stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer

I. Ray-Coquard, N. Casadevall, J. Misset, 2009, Pediatric blood & cancer.

Docetaxel in combination with doxorubicin or vinorelbine.

P. Fumoleau, V. Diéras, J. Misset, 1997, European journal of cancer.

propos de early palliative care

J. Misset, 2011 .

Should FDG PET/CT be used for the initial staging of breast cancer?

D. Groheux, M. Espié, E. Hindié, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment.

J. Misset, G. Mathé, J. Homasson, 1985, Acta vitaminologica et enzymologica.

Correlation between precancerous bronchial metaplasia and cigarette consumption, and preliminary results of retinoid treatment.

J. Misset, G. Mathé, L. Schwarzenberg, 1982, Cancer detection and prevention.

Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.

F. Lévi, H. Bismuth, J. Misset, 1993, European journal of cancer.

HPLC determination of the stability of retinoic acid in ovule formulations for the treatment of cervical dysplasia related to papillomavirus

J. Misset, B. Huynh, G. Fredj, 1995 .

Gemcitabine–Oxaliplatin Combination in Heavily Pretreated Metastatic Breast Cancer: A Pilot Study on 43 Patients

M. Espié, P. Cottu, J. Misset, 2007, The breast journal.

Leukopenic chronic T cell leukemia mimicking hairy cell leukemia: association with human retroviruses.

G. Flandrin, J. Misset, D. Blayney, 1986, Blood.

Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.

E. Van Cutsem, D. Cunningham, J. Armand, 1999, Anti-cancer drugs.

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.

P. Soulié, J. Misset, P. Canal, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.

S. Culine, J. Droz, J. Misset, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin in practice.

J. Misset, 1998, British Journal of Cancer.

Chronotherapy of Colorectal Liver Metastases

F. Lévi, F. Goldwasser, S. Giacchetti, 2002 .

Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials

M. Elman, B. Tombal, E. Raymond, 2004, Clinical Cancer Research.

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study.

P. Soulié, E. Brain, J. Misset, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long‐term maintenance chemotherapy

J. Misset, G. Mathé, D. Machover, 1984 .

Follicular dendritic cell tumor of the mediastinum: expression of fractalkine and SDF-1α as mast cell chemoattractants

P. Validire, J. Misset, A. Anjo, 2006, Virchows Archiv.

A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer.

F. Lévi, H. Bismuth, J. Misset, 1995, The Journal of infusional chemotherapy.

[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].

L. Mauriac, M. Tubiana-Hulin, A. Monnier, 2001, Bulletin du cancer.

Epstein‐Barr virus‐related localized hepatic lymphoproliferative disorders after liver transplantation

E. Raymond, D. Samuel, H. Bismuth, 1995, Cancer.

Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?

J. O’Shaughnessy, A. Seidman, J. Misset, 2002, The oncologist.

Irinotecan-induced immune thrombocytopenia.

P. Bierling, F. Lévi, J. Misset, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study.

J. Trédaniel, G. Zalcman, D. Moro-Sibilot, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of zinc on normal and neoplastic T-lymphocyte proliferation

J. Misset, G. Mathé, M. Gil-delgado, 1985, Medical oncology and tumor pharmacotherapy.

[PET/CT in breast cancer: an update].

D. Groheux, M. Espié, E. Hindié, 2009, Bulletin du cancer.

Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts.

B. Debuire, J. Misset, A. Chabli, 1994, Leukemia.

Chemotherapy for ovarian cancer.

J. Misset, E. Cvitkovic, 1996, The New England journal of medicine.

Chronotherapy of colorectal cancer metastases.

F. Lévi, F. Goldwasser, S. Giacchetti, 2001, Hepato-gastroenterology.

Oxaliplatin: Update on a Active and Safe Dach Platinum Complex

E. Raymond, P. Soulié, J. Misset, 1996 .

Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients

E. Raymond, F. Goldwasser, S. Faivre, 2004, Clinical Cancer Research.

When Should the Immune Clock Be Reset?

Francis Lévi, C. Canon, F. Lévi, 1991 .

Phase I-II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients.

J. Misset, C. Jasmin, A. Descorps-Déclère, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital‐treated rats. characterization and sensitivity to endothall, a protein serine/threonine phosphatase‐2A inhibitor

J. Thiery, J. Misset, A. Anjo, 1999, Hepatology.

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.

F. Lévi, H. Bismuth, J. Misset, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spontaneous or imposed circadian changes in plasma concentrations of 5‐fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer

G Milano, F. Lévi, G. Milano, 1994, Clinical pharmacology and therapeutics.

Implications of chronobiology for 5-fluorouracil (5-FU) efficacy.

F. Lévi, J. Misset, R. Adam, 1993, Advances in experimental medicine and biology.

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.

F. Lévi, J. Misset, P. Lebon, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.

A. Reinberg, F. Lévi, J. Misset, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.

J. Bonneterre, P. Viens, S. Faivre, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

J. Blay, G. Demetri, A. Cesne, 2012, Investigational New Drugs.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

J. Blay, E. Brain, J. Misset, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

M. Espié, D. Rickman, A. de Roquancourt, 2007, PLoS medicine.

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

F. Lévi, S. Giacchetti, C. Focan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinetics of histologic changes in human melanoma after local immunotherapy with BCG

P. Couturier, J. Misset, A. Khalil, 1976, Cancer Immunology, Immunotherapy.

Correlation of bronchial epidermoid metaplasia with level of tobacco consumption in heavy smokers.

J. Misset, G. Mathé, G. Lemaigre, 1986, Cancer detection and prevention.

18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.

E. Hindié, L. Vercellino, J. Misset, 2009, Cancer biotherapy & radiopharmaceuticals.

742 Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea (DD): A prospective assessment

G. Vassal, P. Hérait, S. Giacchetti, 1995 .

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.

F. Goldwasser, J. Misset, F. Trivin, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Short report Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports

F. Goldwasser, F. Trivin, J. Misset, 2005 .

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

M. Uttenreuther-Fischer, F. Joly, J. Gligorov, 2016, SpringerPlus.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

E. Raymond, F. Goldwasser, P. Cottu, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

J. Misset, E. Goldschmidt, E. Cvitkovic, 1997, British Journal of Cancer.

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

M. Espié, A. de Roquancourt, J. Misset, 2007, British Journal of Cancer.

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.

F. Lévi, H. Bismuth, S. Giacchetti, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

T. Petit, V. Diéras, P. Kerbrat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot Study of the Paclitaxel, Oxaliplatin, and Cisplatin Combination in Patients With Advanced/Recurrent Ovarian Cancer

S. Delaloge, J. Misset, E. Cvitkovic, 2000, American journal of clinical oncology.

Oxaliplatin clinical activity: a review.

J. Misset, E. Cvitkovic, H. Bleiberg, 2000, Critical reviews in oncology/hematology.

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

P. Soulié, E. Brain, J. Misset, 1997, European journal of cancer.

Current Considerations in Managing Chemotherapy-induced Nausea and Vomiting

J. Misset, 2007 .

Letter to the editor: Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid

A. Székely, J. Misset, C. Jasmin, 1991 .

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

R. Rouzier, F. Penault-Llorca, A. de Roquancourt, 2015, The oncologist.

Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy.

F. Goldwasser, B. Falissard, J. Misset, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel in advanced gastric cancer

D. Haller, J. Misset, 2002, Anti-cancer drugs.

Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.

V. Diéras, J. Misset, C. Jasmin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma

J. Misset, C. Jasmin, G. Mathé, 1978, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.

M. Campone, P. Fumoleau, S. Delaloge, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin.

P. Soulié, J. Misset, E. Cvitkovic, 1994, Journal of the National Cancer Institute.

The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).

A. Hagenbeek, B. Coiffier, C. Gisselbrecht, 1991, Bone Marrow Transplantation.

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study

M. Nicolson, J. Canon, P. Schőffski, 2012, British Journal of Cancer.

Phase II trial with D‐Trp‐6‐LH‐RH in prostatic carcinoma: Comparison with other hormonal agents

A. Schally, P. Kerbrat, J. Misset, 1986, The Prostate.

An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma

A. Schally, P. Kerbrat, J. Misset, 1984, Medical oncology and tumor pharmacotherapy.

Primary malignant tumors of bone and soft tissues

J. Misset, J. Ziza, N. Delépine, 1998 .

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer

F. Lévi, J. Misset, R. Zidani, 1997, The Lancet.

Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.

F. Goldwasser, J. Misset, F. Lokiec, 2002, European journal of cancer.

Human T-cell lymphotropic virus-1-positive T-cell leukemia/lymphoma in a child. Report of a case and review of the literature.

C. Bodemer, A. Székely, L. Medeiros, 1997, Archives of pathology & laboratory medicine.

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.

F. Goldwasser, J. Misset, E. Cvitkovic, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE).

J. Blay, B. Asselain, S. Koscielny, 2007, Critical reviews in oncology/hematology.

Decision making process in oncology practice: is the information available and what should it consist of?

J. Blay, B. Asselain, S. Koscielny, 2005, Critical reviews in oncology/hematology.

Clinical and pathological response to primary chemotherapy in operable breast cancer.

S Charrier, M. D. De Latour, I. van Praagh, 1997, European journal of cancer.

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, British Journal of Cancer.

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

A. Vincent-Salomon, T. Delozier, M. Namer, 2010, The oncologist.

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

M. Namer, J. Bonneterre, L. Mauriac, 1999, European journal of cancer.

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

R. Kaiser, E. Raymond, F. Goldwasser, 2011, British Journal of Cancer.

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

E. Raymond, F. Goldwasser, S. Faivre, 2006, Investigational new drugs.

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

F. Goldwasser, M. Marty, J. Misset, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mucosal immunity of the female genital tract after HPV infection and vaccination

J. Misset, 2013 .

[Evaluating the benefits of mammographic breast cancer screening].

J. Misset, T. Kullmann, 2010, Orvosi hetilap.

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

D. Sargent, M. Buyse, C. Boni, 2006, Annals of Surgical Oncology.

Primary chemotherapy or hormonotherapy for patients with breast cancer.

E. Brain, J. Misset, J. Rouëss, 1999, Cancer treatment reviews.

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.

B. Weber, P. Fumoleau, L. Vanlemmens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Original article DOI: 10.1093/annonc/mdg449 Phase

P. Fumoleau, V. Diéras, T. Bachelot, 2022 .

DISEASE FLARE INDUCED BY LUTEINISING HORMONE RELEASING HORMONE ANALOGUES IN CANCER PATIENTS

J. Misset, R. Deghenghi, 1984, The Lancet.

A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

L. Zelek, M. Spielmann, E. Brain, 2006, British Journal of Cancer.

Treatment of AIDS-associated Kaposi's sarcoma with oral tretinoin.

J. Misset, C. Jasmin, G. Fredj, 1994, American journal of hospital pharmacy.

Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid.

A. Székely, J. Misset, C. Jasmin, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study 1

J. Schellens, H. Rosing, J. Beijnen, 2000 .

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.

J. Emile, P. Soulié, J. Misset, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.

F. Goldwasser, J. Misset, N. Zeghari-Squalli, 1999, Anti-cancer drugs.

Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.

F. Kreutz, F. Lévi, H. Bismuth, 1999, Anti-cancer drugs.

6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies

A. Mita, P. Soulié, E. Brain, 2005, Journal of Cancer Research and Clinical Oncology.

Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.

L. Zelek, S. Culine, M. Tubiana-Hulin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

P. Soulié, E. Brain, J. Misset, 1999, Journal of Cancer Research and Clinical Oncology.

Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.

F. Goldwasser, M. Marty, J. Misset, 1998, Journal of the National Cancer Institute.

Cancer of the Prostate

D. Khayat, B. Mégarbane, J. Spano, 1998 .

Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment.

J. Misset, G. Mathé, J. Homasson, 1986, Cancer detection and prevention.

Optimization of cisplatin doses in a testicular cancer patient with acute renal failure

J. Misset, F. Lokiec, G. Bousquet, 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[Node negative breast cancer. Beyond international consensus: a pragmatic approach].

T. Delozier, M. Namer, F. Penault-Llorca, 2011, Bulletin du cancer.

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

D. Groheux, M. Espié, E. Hindié, 2008, International journal of radiation oncology, biology, physics.

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.

M. van Glabbeke, P. Fumoleau, V. Diéras, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What is an "elderly" oncologic patient?

J. Misset, C. Bauer, 2008, Critical reviews in oncology/hematology.

Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy.

M. Uttenreuther-Fischer, J. Misset, H. Mont-Serrat, 2010 .

[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)].

C. Tournigand, B. Fervers, A. Bataillard, 2004, Bulletin du cancer.

[Questions on oncology].

J. Misset, 1998, Presse medicale.

Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long‐term maintenance chemotherapy

J. Misset, G. Mathé, D. Machover, 1984, Cancer.

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

S. Iacobelli, F. Lévi, C. Focan, 1993, European journal of cancer.

[Clinical use of oxaliplatin in solid tumors].

F. Goldwasser, J. Misset, 2001, Bulletin du cancer.

Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

J. Fourtillan, J. Misset, J. Vandenbulcke, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of Efficacy of 2-Chlorodeoxyadenoside in the Treatment of Splenic Lymphoma with Villous Lymphocytes

B. Grosbois, X. Troussard, J. Misset, 2000, Leukemia & lymphoma.

Phase I‐II study of aclarubicin for treatment of acute myeloid leukaemia

F. Vassal, H. Tapiero, J. Misset, 1987, European journal of haematology. Supplementum.

704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC)

R. Kaiser, E. Raymond, F. Goldwasser, 2007 .

Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors

F. Lévi, J. Misset, Y. Touitou, 2005, Journal of Cancer Research and Clinical Oncology.

The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of alpha-fetoprotein or beta-human chorionic gonadotrophin: report of two cases.

F. Goldwasser, J. Emile, J. Misset, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Marked 24h Rest / Activity Rhythms Are Associated with Better Quality of Life , Better Response , and Longer Survival in Patients with Metastatic Colorectal Cancer and Good Performance Status 1

J. Lellouch, F. Lévi, S. Giacchetti, 2000 .

To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective Experience

S. Culine, D. Pouessel, J. Misset, 2016, Pathology & Oncology Research.

Phase I Trial of Recombinant Interleukin‐2 Followed by Recombinant Tumor Necrosis Factor in Patients with Metastatic Cancer

D. Blaise, P. Viens, J. Misset, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.